Skip to content
Review Open access

From PCOS to PMOS: insulin resistance, obesity, and the role of GLP-1 receptor agonists in stepwise therapy

Oct 2026 · Lechaschi Vrach · 0 citations

Abstract

Background. In 2026, an international consensus endorsed a new name for polycystic ovary syndrome (PCOS) – "polyendocrine-metabolic ovarian syndrome" (PMOS). The new nomenclature reflects the systemic and pathogenetically heterogeneous nature of the disorder, in which abnormalities of ovulation and steroidogenesis coexist with hyperandrogenism, insulin resistance (IR), overweight, or obesity. IR plays an important role in the pathogenesis of PMOS but is not an essential component of all its phenotypes. Results. This review provides a rationale for a stepwise approach to metabolic therapy in patients with PMOS and overweight or obesity. During the first stage, the primary goals are clinically meaningful weight loss and reduction of metabolic risk. Evidence on the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, is presented. The second stage involves the long-term maintenance of achieved outcomes, including the use of the insulin-sensitizing agents metformin and inositol. Metabolic management should be combined with contraception, endometrial protection, and treatment of the clinical manifestations of hyperandrogenism and anovulatory infertility. Conclusion. In women with polyendocrine-metabolic ovarian syndrome and overweight or obesity, glucagon-like peptide-1 receptor agonists can improve both body weight and metabolic parameters. Available data on semaglutide also suggest the potential to restore regular menstrual cycles and ovulation. An optimal management strategy ensures a seamless transition from active weight loss to long-term maintenance therapy. This may involve continuing pharmacotherapy for obesity and/or insulin-sensitizing agents, such as metformin and inositol. The priority of metabolic correction does not preclude other treatment goals for polyendocrine-metabolic ovarian syndrome, such as endometrial protection, contraception (in the absence of reproductive plans), management of clinical manifestations of hyperandrogenism, and timely treatment of infertility.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.